NRX Pharmaceuticals
Price & Volume
Stats
See more52W Range | $1.62-$5.05 |
Market Cap | $149.3M |
Shares Short | 6M |
Financials
See moreRevenue (12 Mos) | $3.3M |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $1.5M |
Diluted EPS | -$0.49 |
News
See moreYahoo Finance • 9 days ago
NRx targets 2026 KETAFREE approval and outlines SPARC-TMS trial in 400 patients backed by military funding
Yahoo Finance • 19 days ago
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
Yahoo Finance • 19 days ago
NRx Pharma rises as FDA completes initial review of ketamine product
Yahoo Finance • 20 days ago
NRXP: FDA Clears First-Cycle Review Of Preservation-Free Ketamine ANDA; Approval Awaits Vial Cert
About
CEO | Dr. Jonathan C. Javitt M.D., M.P.H. |
CFO | Mr. Michael S. Abrams M.B.A. |
Address | 1201 N. Market Street, Wilmington, DE, United States, 19801 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 29 |